Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection

Carcinoma, Hepatocellular Clinical Trial

Official title: A Exploratory Study of Apatinib Adjuvant Therapy for Hepatocellular Carcinoma With Portal Vein Invasion Who Underwent Radical Resection

Status Recruiting

Clinical Trial Summary

In this phase 2 study, we aim to evaluate the effects and safety of adjuvant apatinib therapy for the patients who underwent R0 resection for hepatocellular carcinoma with portal vein tumor thrombus.

Clinical Trial Description

Portal vein tumor thrombus (PVTT) is one of the characteristics of advanced stage for patients with hepatocellular carcinoma (HCC). There's limited treatment choice for these patients. Even for those who underwent curative resection (R0 resection), the recurrence rate was extremely high. Apatinib is a highly selective VEGFR2 inhibitor and reduces the angiogenesis of tumor efficiently, which had been proven effective in many solid tumors, is a Chinese domestic TKI targeting vascular endothelial growth factor receptor. Phase 2 study of apatinib for patients with advanced HCC had shown signals of clinical efficacy and modest safety. In this study, we aim to evaluate the effects and safety of adjuvant apatinib therapy for the patients who underwent R0 resection for HCC with PVTT. ;

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular

• NCT number: NCT03261791
• Study type: Interventional
• Source: Shanghai Zhongshan Hospital
• Contact: Xiao-Dong Zhu
• Phone: +8602164037181
• Email: zhuxiaodong@gmail.com
• Status: Recruiting
• Phase: Phase 2
• Start date: July 20, 2017
• Completion date: April 20, 2020